BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38123137)

  • 1. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.
    Mo A; Weinkove R; Wood EM; Shortt J; Johnston A; McQuilten ZK;
    Eur J Haematol; 2024 Apr; 112(4):621-626. PubMed ID: 38123137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.
    Mo A; Wood E; Shortt J; Hu E; McQuilten Z
    Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
    Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
    Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.
    Cornelissen LL; Caram-Deelder C; Meier RT; Zwaginga JJ; Evers D;
    Eur J Haematol; 2021 Mar; 106(3):362-370. PubMed ID: 33226659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
    Fricke W; Alling D; Kimball J; Griffith P; Klein H
    Transfusion; 1991 May; 31(4):345-8. PubMed ID: 1823527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
    Estcourt LJ; Desborough M; Brunskill SJ; Doree C; Hopewell S; Murphy MF; Stanworth SJ
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009733. PubMed ID: 26978005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
    Wardrop D; Estcourt LJ; Brunskill SJ; Doree C; Trivella M; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Jul; (7):CD009733. PubMed ID: 23897323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
    Cheok KPL; Chhetri R; Wee LYA; Friel O; Pham A; Salvi A; McRae S; Bardy P; Singhal D; Roxby DJ; Wood EM; Hiwase DK
    Transfusion; 2020 Oct; 60(10):2192-2198. PubMed ID: 32905635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
    Oliva EN; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; Ricco A; Palumbo GA; Impera S; Di Renzo N; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Candoni A; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Bova I; D'Errigo MG; Zini G; Latagliata R
    J Clin Oncol; 2023 Oct; 41(28):4486-4496. PubMed ID: 37294914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
    Tay J; Allan D; Beattie S; Bredeson C; Fergusson D; Maze D; Sabloff M; Thavorn K; Tinmouth A
    BMJ Open; 2016 Oct; 6(10):e013483. PubMed ID: 27798034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.
    Arnold DM; Crowther MA; Cook RJ; Sigouin C; Heddle NM; Molnar L; Cook DJ
    Transfusion; 2006 Aug; 46(8):1286-91. PubMed ID: 16934061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial.
    Estcourt LJ; McQuilten Z; Powter G; Dyer C; Curnow E; Wood EM; Stanworth SJ;
    Trials; 2019 Oct; 20(1):592. PubMed ID: 31615553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
    Estcourt LJ; Malouf R; Doree C; Trivella M; Hopewell S; Birchall J
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012779. PubMed ID: 30221749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic platelet transfusion and risk of bleeding associated with ultrasound-guided central venous access in patients with severe thrombocytopenia.
    Zarama V; Revelo-Noguera J; Quintero JA; Manzano R; Uribe-Buriticá FL; Carvajal DF; Ochoa LM; Valencia-Orozco A; Sánchez ÁI; Ospina-Tascón GA
    Acad Emerg Med; 2023 Jun; 30(6):644-652. PubMed ID: 36587310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia.
    Estcourt LJ; Malouf R; Hopewell S; Doree C; Van Veen J
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011980. PubMed ID: 29709077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high users of platelet transfusions in the neonatal intensive care unit.
    Dohner ML; Wiedmeier SE; Stoddard RA; Null D; Lambert DK; Burnett J; Baer VL; Hunt JC; Henry E; Christensen RD
    Transfusion; 2009 May; 49(5):869-72. PubMed ID: 19175546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
    Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
    Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.